Acute-on-chronic liver failure in patients with metabolic associated fatty liver disease: Past, Present, and Future
DOI:10.3969/j.issn.1001-5256.2021.04.004
- VernacularTitle:代谢相关脂肪性肝病慢加急性肝衰竭的过去、现状与未来
- Author:
Lei MIAO
1
;
Liangjie TANG
;
Jiangao FAN
;
Minghua ZHENG
Author Information
1. NAFLD Research Center/Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China
- Publication Type:Research Article
- Keywords:
Metabolic Associated Fatty Liver Disease;
Acute-On-Chronic Liver Failure;
Liver Transplantation
- From:
Journal of Clinical Hepatology
2021;37(4):761-764
- CountryChina
- Language:Chinese
-
Abstract:
Metabolic associated fatty liver disease (MAFLD) is a hotspot in the field of fatty liver disease at present and it has become the most common chronic liver disease around the world. It is predicted that the incidence rates of MAFLD and related liver cirrhosis will continue to grow in the next 20 years and that they will become new global health issues. Acute-on-chronic liver failure (ACLF) is defined as a clinical syndrome of acute or subacute liver function decompensation within a short period of time in the presence of existing chronic liver diseases, with the main clinical manifestations of ascites, jaundice, coagulation disorder, and hepatic encephalopathy. Based on the existing data, this article discusses the epidemiology, pathogenesis, treatment and management strategies, and future prospects of MAFLD-ACLF.
